急性髓系白血病干细胞及靶向治疗的研究进展

The research progress of the stem cells of acute myeloid leukemia and its targeting treatment

尽管近年来联合化疗的应用使得成人急性髓细胞白血病的治疗取得了长足进步,但总体长期生存率仍不高,主要是复发率高和化疗耐药的影响。白血病干细胞(LSCs)已被确认是白血病复发的根源,随着研究的深入,发现其生物特性也与耐药性相关,这引起了研究人员的特殊关注,进而探究靶向消除白血病干细胞的创新疗法。本综述旨在总结近年来急性髓系白血病干细胞及其靶向治疗的研究进展,探讨治疗该疾病未来可能的研究方向。

Great progress has been recently made in the treatment of adult acute myelogenous leukemia （AML） with the application of combined chemotherapy. However, the overall long-term survival is still lower mainly due to high recurrence rate and resistance to chemotherapy. It is known that leukemia stem cells （LSCs） are most responsible for its relapse, and it is also found that drug resistance is related to their biological properties with the deepening of research work, which results in the particular concern of researchers and draws their attention to exploring an innovative therapy for targeting elimination of leukemia stem cells. In this article, we summarize the recent studies on the stem cells of acute myelogenous leukemia and its targeting therapy and discuss the potential future strategies for the treatment of AML.